• Profile
Close

Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate vs entecavir in the United States

Alimentary Pharmacology and Therapeutics Feb 11, 2022

The first-line treatment agents for chronic hepatitis B virus (HBV) include entecavir (ETV) and tenofovir disoproxil fumarate (TDF). Researchers herein investigated HCC incidence among treatment-naïve patients receiving TDF vs ETV in the United States.

  • A total of 166,933 adults were identified with a diagnosis of chronic hepatitis B and a minimum of 12 months of prior enrolment from a large administrative medical claims database of commercially insured patients; 3,934 of these patients initiated ETV and 6,127 initiated TDF.

  • HCC developed in 90 patients during the follow-up period, including 50 receiving ETV and 40 receiving TDF, giving rise to crude incidence rates of 0.62 per 100 person-years (PY) and 0.30 per 100 PY respectively.

  • Overall findings suggest significantly lower risk of HCC development in correlation with receiving treatment with TDF vs ETV among commercially insured, treatment-naïve patients with chronic hepatitis B in the United States.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay